Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Galectin Therapeutics Inc Receives FDA Fast Track Designation For GR-MD-02 For Fatty Liver Disease With Advanced Fibrosis


Monday, 12 Aug 2013 08:00am EDT 

Galectin Therapeutics Inc announced that the U.S. Food and Drug Administration (FDA) has granted GR-MD-O2 (galactoarabino-rhamnogalacturonate) Fast Track designation for non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver disease with advanced fibrosis. 

Company Quote

5.24
-0.04 -0.76%
4:00pm EDT